Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma
Authors:
- Lesley J. AshtonLALesley J. Ashton
- Jayne E. MurrayJMJayne E. Murray
- Michelle HaberMHMichelle Haber
- Glenn M. MarshallGMGlenn M. Marshall
- David M. AshleyDADavid M. Ashley
- Murray D. NorrisMNMurray D. Norris
- 1 September 2007
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 17 (9) , 709-717
Abstract
Although several studies have shown that drug metabolizing enzyme gene polymorphisms may influence the impact of therapy in childhood leukemia, no comprehensive investigations have been carried out in children with neuroblastoma. The aim of this study was to identify polymorphisms in the genes encoding phase I and II drug metabolizing enzymes associated with the risk of relapse or death in a cohort of 209 children with neuroblastoma. Real-time PCR allelic discrimination was used to characterize the presence of polymorphisms in DNA from children with neuroblastoma. Three broad gene categories were examined: cytochrome P450, glutathione-S-transferase and N-acetyltransferase. Cumulative event-free survival was computed by the Kaplan-Meier method. The influence of selected factors on event-free survival was tested using the Cox proportional hazards model. As previously reported, amplification of MYCN (hazards ratio=4.25, 95% confidence interval=2.76-6.56, P<0.001), unfavorable stage (hazard ratio=4.14, 95% confidence interval=2.3-7.47, P<0.001) or age more than 1 year at diagnosis (hazard ratio=1.86, 95% confidence interval=1.19-2.92, P=0.007) were all associated with an increased risk of relapse or death. Carriers of a NAT1*11 allele variant were significantly less likely to relapse or die compared with those with NAT1*10 or other NAT1 allele variants (P<0.001). In multivariate analysis, children who were GSTM1 null were more likely to relapse or die during follow-up after adjusting for MYCN amplification, stage and age at diagnosis (hazard ratio=1.6, 95% confidence interval=1.02-2.9, P=0.04). These observations suggest that the NAT1*11 variant and the GSTM1 wild-type genotype contribute to a more favorable outcome in patients treated for neuroblastoma and are the first to demonstrate a relationship between NAT1 and GSTM1 genotypes in childhood neuroblastoma.Keywords
This publication has 43 references indexed in Scilit:
- Genetic and epigenetic alterations in neuroblastomaCancer Letters, 2003
- Pharmacogenetics of the major polymorphic metabolizing enzymesFundamental & Clinical Pharmacology, 2003
- Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemiaPharmacogenetics, 2002
- NeuroblastomaDrugs, 2000
- The current contribution of molecular factors to risk estimation in neuroblastoma patientsEuropean Journal of Cancer, 1997
- Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locusHuman Genetics, 1996
- Human Drug-Metabolizing Enzyme Polymorphisms: Effects on Risk of Toxicity and CancerDNA and Cell Biology, 1996
- Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humansPharmacogenetics, 1994
- N-myc genomic content and DNA ploidy in stage IVS neuroblastoma.Journal of Clinical Oncology, 1991
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985